Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Ceftolozane-Tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Mechanisms of Resistance.

Petraitis V, Petraitiene R, Naing E, Aung T, Thi WP, Kavaliauskas P, Win Maung BB, Michel AO, Ricart Arbona RJ, DeRyke AC, Culshaw DL, Nicolau DP, Satlin MJ, Walsh TJ.

Antimicrob Agents Chemother. 2019 Aug 23;63(9). pii: e00344-19. doi: 10.1128/AAC.00344-19. Print 2019 Sep.

PMID:
31235620
2.

Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.

Gómez-Junyent J, Benavent E, Sierra Y, El Haj C, Soldevila L, Torrejón B, Rigo-Bonnin R, Tubau F, Ariza J, Murillo O.

Int J Antimicrob Agents. 2019 May;53(5):612-619. doi: 10.1016/j.ijantimicag.2019.01.010. Epub 2019 Jan 23.

PMID:
30682497
3.

Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa pneumonia in a patient receiving intermittent hemodialysis.

Alessa MA, Almangour TA, Alhossan A, Alkholief MA, Alhokail M, Tabb DE.

Am J Health Syst Pharm. 2018 May 1;75(9):e184-e188. doi: 10.2146/ajhp170056.

PMID:
29691260
4.

In vitro antimicrobial activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis.

Gramegna A, Millar BC, Blasi F, Elborn JS, Downey DG, Moore JE.

J Glob Antimicrob Resist. 2018 Sep;14:224-227. doi: 10.1016/j.jgar.2018.03.002. Epub 2018 Mar 17.

PMID:
29559421
5.

Ceftolozane/tazobactam: place in therapy.

Giacobbe DR, Bassetti M, De Rosa FG, Del Bono V, Grossi PA, Menichetti F, Pea F, Rossolini GM, Tumbarello M, Viale P, Viscoli C; ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva).

Expert Rev Anti Infect Ther. 2018 Apr;16(4):307-320. doi: 10.1080/14787210.2018.1447381. Epub 2018 Mar 9. Review.

Supplemental Content

Loading ...
Support Center